Hainan Haiyao Co., Ltd.

000566

CNE0000004W8

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-05-30 pm EDT			5-day change	1st Jan Change
3.35 ^CNY	+2.76%		-1.76%	-25.88%

Apr. 29	Hainan Haiyao Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	Hainan Haiyao Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Hainan Haiyao Co., Ltd. Approves Dividend for 2016; Approves the Election of Directors

May 22, 2017 at 11:32 am EDT

Hainan Haiyao Co., Ltd. approved a dividend of CNY 1.5000 per ten shares (tax included) for 2016.

The company also approved the election of Chen Yihong, Ren Rongbo, Bai Zhiquan, Qiu Wanping, as non-independent directors. Cai Donghong, Zeng Yu and Meng Zhaosheng were appointed as independent directors of the company.

Latest news about Hainan Haiyao Co., Ltd.

Hainan Haiyao Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Hainan Haiyao’s Antibiotic Passes Generic Evaluation	Jan. 31	MT
Hainan Haiyao's Unit Gets Nod to Become Marketing License Holder of Shuangshen Huoxue Tongluo Granules	Dec. 08	MT
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
China Sanctions Hainan Haiyao, Former Vice Chairman Over Information Disclosure Violations	23-10-05	MT
Hainan Haiyao Co., Ltd.(XSEC:000566) added to S&P Global BMI Index	23-09-18	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Hainan Haiyao Unit Receives 1.2 Million Yuan Government Subsidy	23-08-21	MT
Hainan Haiyao Co., Ltd. Announces Management Changes	23-06-01	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-10	CI
Hainan Haiyao Unit's Minocycline Hydrochloride Capsules Passes Drug Regulator's Evaluation	23-03-08	MT
Hainan Haiyao Unit Gets Regulatory Nod for Antibacterial Drug	23-01-31	MT
Hainan Haiyao Gets Regulatory Nod for Anti-Skin Disease Drug	23-01-09	MT
Xinxing Cathay International Capital Holdings Limited agreed completed the acquisition of 43% stake in Shanghai Listent Medical Tech Co., Ltd. from Hainan Haiyao Co., Ltd.	23-01-06	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-27	CI
Xinxing Cathay International Capital Holdings Limited agreed to acquire a 43% stake in Shanghai Listent Medical Tech Co., Ltd. from Hainan Haiyao Co., Ltd. for approximately CNY 240 million.	22-10-20	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Hainan Haiyao to Sell 43% Stake in Medical Technology JV	22-08-04	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-28	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-26	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-22	CI
Hainan Haiyao Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-25	CI
Tempus : Subsidiary Disposing Two Companies	21-06-30	MT

Chart Hainan Haiyao Co., Ltd.

Duration

Period

More charts

Company Profile

HAINAN HAIYAO CO., LTD. is a China-based company principally engaged in the research, development, manufacture and sale of medicines and medical instrument. The Companyâs main products consist of six categories, including cephalosporin series, stomach and intestine medicines, anti-tumor medicines, cochlear implant series, bulk drugs and intermediate series. The Company distributes its products in domestic market and to overseas market, with China as its main market.

Sector

Pharmaceuticals

Calendar

2024-08-28 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HAINAN HAIYAO CO., LTD.	-25.88%	600M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B